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The tumor suppressor PML was originally identified as the gene
fused to RARα by the t(15;17) chromosomal translocation
unique to acute promyelocytic leukemia (APL). Although still
incompletely understood, there is good evidence that the
PML/RARα fusion protein exerts its oncogenic effects by inter-
fering with the function of both RARα and PML.The role of PML
in normal cells has been carefully examined in mice with genet-
ic manipulations of PML. Mice with a genetic deletion in PML
are viable and develop normally, although they are prone to
mycotic infections (Wang et al., 1998a). However, PML−/− mice
are more susceptible to carcinogen-induced tumor formation
than their wild-type counterparts. Evidence that PML plays an
important role in apoptosis was provided by experiments show-
ing that mouse embryo fibroblasts from PML−/− mice are signifi-
cantly protected against several apoptotic inducers, including γ
irradiation, Fas, TNF, IFN, and ceramide (Wang et al., 1998c).
This is consistent with results from PML/RARα transgenic ani-
mal models of APL, where hematopoietic cells expressing
PML/RARα have altered PML function and are less sensitive to
the effects of the same apoptosis inducers (i.e., TNF and IFNs)
on colony formation (Wang et al., 1998c).These mice develop a
preleukemic state that progresses to APL; however, this hap-
pens with a low frequency and over several months (Grisolano
et al., 1997; Wang et al., 1998a). When they are crossed with
PML−/− mice, further reducing PML function, the incidence of
leukemia is increased and hastened, suggesting that PML has
proapoptotic functions in malignant or premalignant cells (Rego
et al., 2001).
Wild-type PML localizes to the nuclear bodies (NBs), also
known as PML oncogenic domains (PODs), and is required for
their proper formation. Deletion of PML, as well as expression of
PML/RARα, causes disruption of the NBs (Melnick and Licht,
2000; Wang et al., 1998a). Within the NBs, PML has been
shown to interact with p53, pRb, DAXX, and CBP.Two other pro-
teins that localize to PML NBs are the ubiquitin-conjugating
enzyme Ubc9 and SUMO-1, which coordinate to modify the
PML protein. Ubc9 binds PML and mediates the conjugation of
SUMO-1 to PML. There is significant debate about how sumoy-
lation of PML affects its function. Expression in PML−/− cells of a
PML mutated in its three sumoylatable lysine residues is unable
to rescue NB formation (Zhong et al., 2000). However, if the
lysine residue within the RING domain of PML that binds Ubc9
and SUMO-1 is mutated, there is no dysfunction of NB forma-
tion (Boddy et al., 1997). Sumoylation may also regulate the
binding of PML to other NB constituents and, as a result, regu-
late the movement of these proteins in and out of the NB. The
identification of desumoylases indicates that sumoylation is a
dynamic process with potential points of regulation within cells.
New data from the Hayakawa article suggest that the sumoyla-
tion of PML may be further regulated by its phosphorylation
state, and that this regulation is linked to the ability of PML to
induce apoptosis.
The authors show that As2O3 activates ERK, defining PML
as a novel target for As2O3-induced, ERK-mediated phosphory-
lation. They confirm that PML is sumoylated in response to
As2O3 treatment and show that a pharmacologic ERK inhibitor
can block this sumoylation. They further link these events to
apoptosis. Cells transfected with PML, Ubc9, and SUMO-1
were significantly more sensitive to As2O3-induced apoptosis
than those transfected with PML alone. In addition, the onco-
genic PML/RARα protein is a target for As2O3-induced phos-
phorylation. However, Hayakawa and Privalsky did not find
sumoylation of PML/RARα when expressed with Ubc9 and
Sumo, consistent with previous reports that PML/RARα is less
sensitive than PML to sumoylation (Kamitani et al., 1998a,
1998b). They further correlated this reduced sumoylation with
the failure of transiently transfected PML/RARα to enhance
arsenic-induced apoptosis. These results are consistent with
our previous results that stable expression of PML/RARα in
U937 cells has a minimal effect on arsenic sensitivity (Davison
et al., 2003). The finding that a chemical inhibitor nevertheless
decreases the sensitivity of APL cells to arsenic may point to
involvement of additional MAPK pathways in cell death by
arsenic, as suggested by others (Davison et al., 2003; Kyriakis
and Avruch, 1996; Verma et al., 2002).
There are many examples of how one posttranslational
modification can affect another. Here, phosphorylation in both
the N and C termini of PML potentiates sumoylation.
Phosphorylation has also been shown to enhance sumoylation
of heat shock factor 1 and the transcription factor, Smad4
(Hietakangas et al., 2003; Ohshima and Shimotohno, 2003).
However, the sumoylation of several other transcription factors,
c-jun, p53, and Elk-1, is abrogated by phosphorylation (Muller
et al., 2000;Yang et al., 2003). In the case of c-jun, this is further
complicated by the fact that ubiquitination is decreased as well
as sumoylation. This is in contrast to IκB, the inhibitor of NF-κB
signaling, where phosphorylation decreases sumoylation and
increases ubiquitination, thereby marking the protein for degra-
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PML is a multifunctional protein that plays an important role in programmed cell death, albeit by mechanisms that remain
unclear. In this issue of Cancer Cell, Hayakawa and Privalsky associate a MAP kinase pathway that mediates As2O3-induced
PML phosphorylation with sumoylation and increased apoptotic activity of PML.Thus, specific MAP kinases may potentiate
apoptosis in response to As2O3, a compound that has dramatic activity against acute promyelocytic leukemia (APL) cells.This
novel mechanism may have important implications for use of As2O3 as a chemotherapeutic agent, especially in malignancies
less sensitive to As2O3 than APL.
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dation (Desterro et al., 1998). The regulation of protein function
by posttranslational modifications is likely to be protein-specific
and merits further investigation.
It is unclear what relevance the position of phosphorylation
and sumoylation sites may have on each other. Of note, the N-
terminal phosphorylation site is adjacent to the RING box of
PML where Ubc9 and SUMO bind. Are there physical interac-
tions between the RING box and the C-terminal portion of PML?
Clarification of this awaits the three-dimensional structure of
PML, but to date, only the structure of the RING domain has
been resolved.
ERK phosphorylation of PML is clearly linked to its sumoy-
lation, but how do these protein modifications lead to increased
apoptosis? DAXX is a protein that bridges the signaling
between death receptors at the cytoplasmic membrane and the
nucleus. PML and DAXX interact directly within the NBs and
cooperate to increase FAS-mediated apoptosis (Torii et al.,
1999). In addition, small-interfering RNA to DAXX decreases
As2O3-induced apoptosis (Kawai et al.,
2003). In two models suggested by
Bernardi and Pandolfi, PML interacts
with DAXX to either enhance transcrip-
tion of proapoptotic genes or interfere
with its function as a transcriptional
repressor of antiapoptotic genes
(Bernardi and Pandolfi, 2003). Perhaps
PML, which is both phosphorylated and
SUMO-1-modified, interacts more effec-
tively with DAXX to enhance cell death.
Recently, As2O3 has been shown to
increase the association of another
kinase, ZIPK, with the NBs, which in turn
may recruit DAXX (Kawai et al., 2003).
Perhaps As2O3-induced sumoylation of
PML increases the recruitment of ZIPK
and DAXX to NBs.
Some key questions remain unan-
swered. First, there is the paradox of how
As2O3 can enhance sumoylation of PML
and apoptosis and yet cause PML degra-
dation. As2O3 also degrades PML/RARα,
which led to the hypothesis that As2O3
differentiates APL cells by degrading the
dominant-negative effect of PML/RARα
on RA and PML signaling. One possibili-
ty is that PML sumoylation activates a death pathway and then
signals a degradation of the protein. The authors show that
As2O3 sumoylates PML very soon after treatment (i.e., partially
by 1 hr and maximally after 6 hr). In our hands, PML/RARα, at
least, is not degraded after 6 hr, but only after 18–24 hr (our
unpublished data). As2O3-induced sumoylation of PML causes
proteasome components to colocalize near the NBs and
recruits DAXX and other proapoptotic machinery to the NBs,
while the non-sumoylatable PML mutant does not (Lallemand-
Breitenbach et al., 2001). SUMO-modification of a protein may
not directly mark proteins for degradation, but could possibly
change their subcellular localization or facilitate ubiquitination
(Melchior, 2000). As2O3 may bring the proteasome to meet the
sumoylated PML, resulting in degradation (Lallemand-
Breitenbach et al., 2001). Of interest, degradation of
PML/RARα by RA is associated with the expression of UBE1L,
a ubiquitin-activating E1-like enzyme, although the relevance of
this to As2O3-induced PML/RARα degradation is unresolved
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Figure 1. A model of PML-dependent and -inde-
pendent As2O3-induced apoptosis
The upper panel represents 16 hr after As2O3
treatment. ERK and JNK are phosphorylated (P)
and thereby activated. JNK may activate pro-
apoptotic genes via AP-1 binding or may mod-
ulate bcl-2/BH3 proteins. ERK phosphorylates
PML, which is subsequently sumoylated (S).
DAXX is translocated from the cell membrane to
the nuclear bodies (NB), where it forms a com-
plex with PML and ZIPK. The result of these bind-
ing is to turn on transcription of proapoptotic
genes. Proteasomal components (11s and 20s)
relocalize near or at NBs. The bottom panel rep-
resents later time points of at least 1824 hr after
As2O3 exposure. Sumoylated PML is potentially
ubiquitinated (Ub) and degraded by the pro-
teasome.
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(Kitareewan et al., 2002).
Second, As2O3 alters many cellular signaling molecules
and pathways. There is considerable evidence that additional
signaling mechanisms, at least some of which are PML-inde-
pendent, must be involved in As2O3-induced apoptosis.
Although resistant to many apoptotic stimuli, fibroblasts with a
genetic deletion in PML are as sensitive as wild-type fibrob-
lasts to the cytotoxic effects of As2O3 and other arsenic-con-
taining compounds (Wang et al., 1998b). Hayakawa and
Privalsky find that addition of PML and the constitutively active
MEK1 did not cause apoptosis and conclude that other factors
are required for cell death. The induction of reactive oxygen
species by As2O3 is important for its ability to induce death
(Davison et al., 2003). Perhaps this change in redox puts the
cell in a state favoring apoptosis that is enhanced by ERK sig-
naling and subsequent sumoylation of PML. This hypothesis is
supported by recent data showing TPA-enhanced, As2O3-
induced apoptosis is associated with enhanced ERK activa-
tion and decreased glutathione levels (Fernandez et al.,
2004). Another kinase, JNK, is activated by As2O3 and is a
mediator of As2O3-induced apoptosis in APL cells (Davison et
al., 2004). Whether this is mediated by activation of AP-1 tran-
scription of proapoptotic genes or through effects on bcl-
2/BH3 domain proteins remains unclear. It would be
interesting to see if PML is also a target for JNK phosphoryla-
tion and if the ability of As2O3 to sumoylate PML correlates
with increased activation of JNK. Importantly, many of the
effects of As2O3 may be cell-type specific. In both neurons and
leukemic cells, p38 Map kinase is activated in response to
arsenic treatment. In neurons, a p38 inhibitor blocked arsenic-
induced apoptosis; however, in leukemic cell lines, the same
inhibitor did not block apoptosis, but rather slightly enhanced it
(Namgung and Xia, 2000; Verma et al., 2002). Thus, it will be
interesting to determine the generality of the ERK-PML path-
way in mediating apoptosis.
Despite lingering questions concerning mechanisms, this
PML-ERK connection may potentially be exploited to enhance
As2O3 clinically. Although As2O3 is used to treat APL and shows
some promise as a treatment for patients with multiple myeloma
or myelodysplastic syndrome, it has less antitumor activity
against other tumor types. Therefore, many groups are investi-
gating the possibility of combining As2O3 with other drugs,
including both conventional cytotoxic agents and more novel,
targeted agents. The new data of Hayakawa and Privalsky sug-
gest that agents that activate or amplify ERK signaling may
enhance the sensitivity of tumors to As2O3, perhaps especially
those that express significant levels of PML.
A proposed model for As2O3-induced apoptosis is shown in
Figure 1, which includes both PML-dependent and -indepen-
dent pathways. This model is by no means exhaustive, and fur-
ther investigation is required to link all the elements. As
illustrated in PML−/− fibroblasts, PML expression enhances
many apoptosis inducers, but surprisingly not As2O3. Together,
these data serve to emphasize the unique aspects of As2O3 as
an apoptosis inducer that have yet to be explored.
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